New Amsterdam Pharma
Founded Year
2019Stage
Reverse Merger | IPOTotal Raised
$196MMarket Cap
4.06BStock Price
36.14Revenue
$0000About New Amsterdam Pharma
New Amsterdam Pharma focuses on the development of treatments for cardiovascular disease and other lipid-related conditions within the pharmaceutical industry. The company is advancing a novel approach to lipid-lowering therapy through cholesteryl ester transfer protein (CETP) inhibition and aims to reduce the risk of cardiovascular disease. New Amsterdam Pharma primarily sells to the healthcare sector, focusing on patients with unmet needs in cardiovascular disease management. It was founded in 2019 and is based in Naarden, Netherlands.
Loading...
Loading...
Latest New Amsterdam Pharma News
Oct 15, 2025
Caristo Diagnostics, which uses AI to detect the earliest signs of heart disease on cardiac CT scans, will play a major role in an upcoming study of NewAmsterdam Pharma’s cholesterol-lowering drug candidate obicetrapib.
New Amsterdam Pharma Frequently Asked Questions (FAQ)
When was New Amsterdam Pharma founded?
New Amsterdam Pharma was founded in 2019.
Where is New Amsterdam Pharma's headquarters?
New Amsterdam Pharma's headquarters is located at Gooimeer 2-35, Naarden.
What is New Amsterdam Pharma's latest funding round?
New Amsterdam Pharma's latest funding round is Reverse Merger.
How much did New Amsterdam Pharma raise?
New Amsterdam Pharma raised a total of $196M.
Who are the investors of New Amsterdam Pharma?
Investors of New Amsterdam Pharma include Frazier Lifesciences, EQT Life Sciences, Medpace, Presight Capital, Ascendant Capital and 11 more.
Loading...
Loading...